Nature Biotechnology paper introduces MOLEA, a single-pass AI for multi-objective drug design
MOLEA reports simultaneous optimization of potency, selectivity, and safety in one go, challenging the usual one-property-at-a-time workflows in AI-assisted drug design.
By Ryan Merket · Published
Primary source: X
Why it matters
If MOLEA truly balances potency, selectivity, and safety in one pass, it could shorten design cycles and reduce rework in AI-driven drug discovery, a key bottleneck for biotech teams.
Researchers publishing in Nature Biotechnology introduced MOLEA, an AI framework that aims to optimize potency, selectivity, and safety in a single pass, according to a brief post on X.